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longer (13.44 days) than those with a CRP less than 25 mg/L 
(8.18 days). These findings are consistent with the results from 
a previous study.[3]
But do these findings mean that we are nearer to using CRP in 
routine clinical practice for the diagnosis and monitoring of  the 
progress of  influenza infection?
Firstly, CRP by itself, although highly sensitive, is non-specific 
for many inflammatory diseases including bacterial and to a 
lesser degree, viral infections.[4] The non-specific property of  
the acute-phase protein renders CRP a low discriminatory value 
for diagnostic purposes, especially in an emergency department.
Inflammatory mediators such as tumor necrosis factor and 
interleukins stimulate hepatic synthesis of  CRP.[5] CRP in turn, 
induces tissue factor expression by monocytes, thereby increasing 
procoagulant activities.[6] In fact, this is probably one of  the 
reasons why increased levels of  CRP is associated with increased 
risk of  coronary thrombosis and cerebrovascular thrombosis.[1,3]
Generally, CRP level in a healthy person is usually lower than 
10 mg/L, although higher levels can be found with increasing 
age. There is no difference in mean concentrations between men 
and women although higher levels are found late in pregnancy. 
This increase in CRP usually takes place in the first 6 to 8 h 
and can reach peak levels approaching 350–400 mg/L after 
approximately 48 h.[7]
On the other hand, once the inflammation resolves, the CRP level 
rapidly declines too with an elimination half-life of  about 4 – 9 
hours.[7] While a non-specific marker, this property of  rapid rise 
and fall in tandem with the progression and decline of  infections 
gives CRP an advantage point as a marker for disease activity.[7] 
As mentioned, viral infections and any mild inflammation elicit 
a smaller increase in CRP level (10–40 mg/L), while bacterial 
infection as well as active inflammation can elicit much higher 
responses of  between 40–200 mg/L. In some severe bacterial 
infections and burns, the level can increase more than 200 
mg/L.[7]
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Influenza viral infection is a common and potentially fatal 
respiratory infection, particularly when the inflicting strain is an 
antigenetically novel strain that can result in severe manifestations 
(e.g., recent H1N1 epidemic). C-reactive protein (CRP) is a 
classical acute phase protein that is extremely sensitive but non-
specific biomarker in many systemic inflammatory processes.[1]
Discovered in 1930, CRP was so-named because it was first 
found to have reacted with the C-polysaccharide of  cell walls 
of  pneumococci to form precipitate.[2] Physiologically, this 
pentameric protein secreted from the hepatocytes is an important 
component of  the innate immune response to inflammation and 
infection. By binding to phosphocholine, polysaccharides, and 
peptidopolysaccharides found in bacteria, fungi, and parasites, it 
activates the classical complement pathway through C1q, binding 
directly to the Fc portion of  IgG, stimulating releases of  IL-1 
and TNF-a in macrophages, and thereby, enhances phagocytosis 
of  foreign substances.[1]
In this issue, the authors of  the article Correlation of  C-reactive 
Protein to Severity of  Symptoms in Acute Influenza A Infection 
demonstrated a correlation between the severity of  influenza 
symptoms with the initial CRP level. In that study, patients with 
symptoms suggestive of  influenza were screened with Enzyme-
Linked ImmunoSorbent Assay (ELISA). Patients suspected of  
having bacterial infection or concurrent bacterial infections were 
excluded. It was shown that patients with CRP values greater than 
25mg/L had an average symptom duration that was significantly 
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Nonetheless, severe infections itself  is prothrombotic.[8] For 
example, exposure to bacterial endotoxins triggers release of  
various inflammatory cytokines,[8,9] particularly tumor necrosis 
factor α, interleukin-1β, and interleukin-6. These cytokines are 
capable of  activating coagulation and inhibiting fibrinolysis, and 
the procoagulant thrombin is capable of  further stimulating 
multiple inflammatory pathways.[9] Eventually, all these pathways 
lead to widespread endothelial injury, resulting in further 
microthrombosis, and thus, adding more confusion to this 
conundrum. In other words, although the high level of  CRP 
may be due to severe influenza infections, but perhaps, a severe 
infection itself  triggers a more extensive thrombosis, and this 
thrombosis itself  is a triggering factor for the higher CRP level. [10] 
Is the high level of  CRP due to the infection severity itself  or 
it is because of  associated thrombosis? Furthermore, CRP 
causes further thrombosis by inhibiting fibrinolytic activities 
and inducing plasminogen activator inhibitor-1 (PAI-1) release 
from endothelial cells.[10]
Arguably, however, one might say that other non-specific 
markers have also been used successfully and indispensably 
for certain infections, for example, platelet counts for dengue 
fever. But in such cases, the biomarker abnormality is a specific 
feature of  the infection itself, rather than just an association. 
The primary question we need to explore therefore is whether 
CRP abnormality a specific feature of  influenza or it is just an 
association.
Second, influenza is such a common and self-limiting disease that 
it is impractical to investigate every cough and cold cases. In fact, 
we often do not routinely do specialized laboratory investigations 
to differentiate bacterial from viral origin of  a patient with upper 
respiratory tract infections other than relying on clinical cues: if  
the symptom duration persists longer than the first 5–7 days, a 
bacterial origin should be suspected. In fact, in this current study, 
the authors have to take every measure to ensure that the etiology 
of  the patient’s symptoms is not due to a bacterial or concurrent 
bacterial origin other than the influenza itself. Furthermore, to 
specifically pinpoint to influenza A virus requires either viral 
culture or in this particular study, a positive ELISA assay for 
influenza A antigen. In many laboratories around the world, 
these specific tests are not readily available, are too costly for 
routine testing, or not available easily as a bedside investigative 
tool in emergency departments or wards. As such, it is not a cost-
effective measure to diagnose influenza A unless an epidemic 
of  a novel influenza antigen has emerged again as an outbreak.
Other questions that should be addressed include: Does this 
increasing trend in CRP occur specifically in influenza A? How 
about the trends in other viruses? How do we differentiate them? 
In a study done previously, both rhinovirus and influenza virus 
cause increase in CRP.[11] In fact, previous studies have shown that 
most viral infections are associated with a modest CRP elevation 
of  about 20 to 40 mg/L, although greater elevations of  more 
than 100 mg/L may occur in infections caused by adenovirus, 
influenza, measles, mumps, and varicella.
Even if  a biomarker were to be used routinely to monitor the 
progress of  influenza infection, is CRP the most suitable choice? 
In a comparative study on the trend of  CPR versus that of  serum 
amyloid A (SAA) protein in experimental inflammation, it is 
shown that the increase of  CRP was less marked as compared 
to that of  SAA, suggesting that SAA may in fact, be a more 
sensitive marker.[11]
Nonetheless, because of  its rapid rise and fall in relation to the 
severity of  inflammation, CRP is probably a better marker than 
erythrocyte sedimentation rate (ESR). While CRP level returns 
to normal quickly upon resolution of  the inflammatory insult, 
ESR level may not return to normal for several weeks despite 
clinical improvement.[7] Furthermore, the CRP levels are not 
affected by anemia, polycythemia, protein level, etc. It is also 
minimally affected by the patient’s age as well as gender.[7] On 
the other hand, these factors mention can affect the ESR level.[7]
As such, albeit non-specific, CRP has been used as a biomarker 
for the inflammatory diseases such as appendicitis, cholecystitis, 
pancreatitis, pelvic inflammatory disease, pneumonia, urinary 
tract infection, and meningitis.[7] Still, another question that need 
to be conclusively answered is whether the different types of  
influenza viruses elicit varied degree of  CRP response. Influenza 
viruses are notoriously known to have show great antigenic 
diversity. Of  the three types of  influenza viruses—A, B, and 
C—only types A and B cause widespread outbreaks.[12] Is CRP, 
therefore, a sensitive marker for influenza A and B only? Is there 
any difference between these two responses?
Influenza A viruses are further classified into subtypes based on 
antigenic differences between their two surface glycoproteins, 
hemagglutinin and neuraminidase. There are approximately 
15 hemagglutinin subtypes (H1–H15) and nine neuraminidase 
subtypes (N1–N9) for influenza A viruses. Viruses of  all 
hemagglutinin and neuraminidase subtypes have been discovered 
from aquatic birds, but only three hemagglutinin subtypes (H1, 
H2, and H3) and two neuraminidase subtypes (N1 and N2) 
have stable lineages in the human population.[12] Does CRP elicit 
different responses in all these different subtypes?
Perhaps CRP is a more useful marker for neonates. Previous 
studies have shown that CRP is the single best biomarker in early 
detection of  neonatal septicemia, and that serial measurements 
correspond to the course of  the infection, particularly after the 
first three day of  life. In neonates, CRP is also a useful marker 
to monitor for the efficacy of  antibiotic treatment.[7]
As a whole, the results from this study represent yet another step 
towards exploring further uses of  this ubiquitous biomarker. But 
perhaps, at this stage, it is more appropriate to say that CRP does 
correlates with the severity of  viral infections in general, rather 
than specifically for influenza A infection. Secondly, perhaps 
measuring the trend of  serial CRP level is more useful than the 
absolute level itself. Nonetheless, influenza, being such a common 
infectious disease, is self-limiting in most cases. Unfortunately, 
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it can also vary from symptomless infection to the most severe 
course of  illness, and in some cases, death. Furthermore, 
specifically within the context of  pneumonia, CRP is not useful for 
discriminating between bacterial and viral infections although as 
mentioned earlier, the increase in response of  bacterial infections 
is generally bigger than that of  viral infections.[7] In this regard, for 
lung infections, CRP is found to be useful marker more as a guide 
to monitor response to antibiotic treatment as well as monitoring 
for the development of  complications. In other words, although 
higher CRP levels usually correspond to bacterial pneumonia, 
especially due to Streptococcus pneumoniae, the ED management 
should be based on traditional parameters and clinical assessment 
rather than on the CRP level. In fact, there is no data to suggest 
that CRP is a better prognostic indicator than clinical indicators 
secondary to pneumonia. Nonetheless, an elevated CRP level 
greater than 100 mg/L often indicates treatment failure.[7]
In conclusion therefore, the ultimate question is not whether 
CRP can be used to monitor the progress of  infection, but rather, 
the question is should it be used, and even if  it should be used, 
when it should be used.
REFERENCES
1. Pepys MB, Hirschfield GM. C-reactive protein: A critical update. J Clin 
Invest 2003;111:1805-12.
2. Tillett WS, Francis T. Serological reactions in pneumonia with a non-protein 
somatic fraction of  pneumococcus. J Exp Med 1930;52:561-71.
3. Falsey AR, Walsh EE, Francis CW, Looney RJ, Kolassa JE, Hall WJ, et al. 
Response of  C-reactive protein and serum amyloid A to influenza A 
infection in older adults. J Infect Dis 2001;183:995-9.
4. Jaye DL, Waites KB. Clinical applications of  C-reactive protein in pediatrics. 
Pediatr Infect Dis J 1997;16:735-46; quiz 46-7.
5. Gabay C, Kushner I. Acute-phase proteins and other systemic responses 
to inflammation. N Engl J Med 1999;340:448-54.
6. Nakagomi A, Freedman SB, Geczy CL. Interferon-gamma and 
lipopolysaccharide potentiate monocyte tissue factor induction by 
C-reactive protein: Relationship with age, sex, and hormone replacement 
treatment. Circulation 2000;101:1785-91.
7. Clyne B, Olshaker JS. The C-reactive protein. J Emerg Med 1999;17:1019-25.
8. Vallet B. Microthrombosis in sepsis. Minerva Anestesiol 2001;67:298-301.
9. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-
Rodriguez A, et al. Efficacy and safety of  recombinant human activated 
protein C for severe sepsis. N Engl J Med 2001;344:699-709.
10. Zouaoui Boudjeltia K, Piagnerelli M, Brohee D, Guillaume M, Cauchie P, 
Vincent JL,et al. Relationship between CRP and hypofibrinolysis: Is this a 
possible mechanism to explain the association between CRP and outcome 
in critically ill patients? Thromb J 2004;2:7.
11. Whicher JT, Chambers RE, Higginson J, Nashef  L, Higgins PG. Acute 
phase response of  serum amyloid A protein and C reactive protein to the 
common cold and influenza. J Clin Pathol 1985;38:312-6.
12. Nicholson KG, Wood JM, Zambon M. Influenza. Lancet 2003;362:1733-45.
How to cite this article: Chew KS. What's new in Emergencies 
Trauma and Shock? C-reactive protein as a potential clinical 
biomarker for influenza infection: More questions than answers. J 
Emerg Trauma Shock 2012;5:115-7.
Received: 02.12.11. Accepted: 01.01.12.
